Abstract

One strategy for treating methamphetamine and similar compound addictions is the use of immunopharmacotherapeutics to elicit production of antibodies, which will bind the drugs of abuse and alter their pharmacokinetic properties in a manner that reduces or eliminates drug use. An added advantage is that immunopharmacotherapies can be used in combination with other medications to obtain an addictive or synergenic effect. This supplement to R37DA005477 involves designing, synthesizing, and coupling methamphetamine haptens to appropriate proteins (BSA, OVA, others) and to produce conjugates for use in developing monoclonal antibodies as pharmacotherapies to treat methamphetamine and other stimulant addictions.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
3R37DA005477-18S1
Application #
7475980
Study Section
Special Emphasis Panel (NSS)
Program Officer
Shih, Ming L
Project Start
1988-07-01
Project End
2008-06-30
Budget Start
2005-07-01
Budget End
2008-06-30
Support Year
18
Fiscal Year
2007
Total Cost
$156,322
Indirect Cost

  Institution

Name
Research Triangle Institute
Department
Type
DUNS #
004868105
City
Research Triangle
State
NC
Country
United States
Zip Code
27709

  Publications

Carroll, F Ivy; Kosten, Thomas R; Buda, Jeffrey J et al. (2018) A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336. Front Pharmacol 9:712
Rüedi-Bettschen, Daniela; Wood, Sherri L; Gunnell, Melinda G et al. (2013) Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine 31:4596-602
Andersen, Monica L; Sawyer, Eileen K; Carroll, F Ivy et al. (2012) Influence of chronic dopamine transporter inhibition by RTI-336 on motor behavior, sleep, and hormone levels in rhesus monkeys. Exp Clin Psychopharmacol 20:77-83
Carroll, F Ivy; Blough, Bruce E; Pidaparthi, Ramakrishna R et al. (2011) Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 54:5221-8
Czoty, Paul W; Martelle, Jennifer L; Carroll, F Ivy et al. (2010) Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates. Pharmacol Biochem Behav 96:274-8
Laurenzana, Elizabeth M; Hendrickson, Howard P; Carpenter, Dylan et al. (2009) Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine 27:7011-20
Jin, Chunyang; Navarro, Hernán A; Ivy Carroll, F (2009) Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters. Bioorg Med Chem 17:5126-32
Carroll, F Ivy; Abraham, Philip; Gong, Paul K et al. (2009) The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 52:7301-9
Navarro, Hernan A; Howard, James L; Pollard, Gerald T et al. (2009) Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 156:1178-84
Jin, Chunyang; Navarro, Hernan A; Carroll, F Ivy (2008) Development of 3-phenyltropane analogues with high affinity for the dopamine and serotonin transporters and low affinity for the norepinephrine transporter. J Med Chem 51:8048-56

Showing the most recent 10 out of 19 publications